These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 11948132)

  • 21. Cellular pharmacology of gemcitabine.
    Mini E; Nobili S; Caciagli B; Landini I; Mazzei T
    Ann Oncol; 2006 May; 17 Suppl 5():v7-12. PubMed ID: 16807468
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hyperthermia inhibits recombination repair of gemcitabine-stalled replication forks.
    Raoof M; Zhu C; Cisneros BT; Liu H; Corr SJ; Wilson LJ; Curley SA
    J Natl Cancer Inst; 2014 Aug; 106(8):. PubMed ID: 25128695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation.
    Ewald B; Sampath D; Plunkett W
    Mol Cancer Ther; 2007 Apr; 6(4):1239-48. PubMed ID: 17406032
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of thymidylate synthase by 2',2'-difluoro-2'-deoxycytidine (Gemcitabine) and its metabolite 2',2'-difluoro-2'-deoxyuridine.
    Honeywell RJ; Ruiz van Haperen VW; Veerman G; Smid K; Peters GJ
    Int J Biochem Cell Biol; 2015 Mar; 60():73-81. PubMed ID: 25562513
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hydroxyurea decreases gemcitabine resistance in pancreatic carcinoma cells with highly expressed ribonucleotide reductase.
    Funamizu N; Kamata Y; Misawa T; Uwagawa T; Lacy CR; Yanaga K; Manome Y
    Pancreas; 2012 Jan; 41(1):107-13. PubMed ID: 21926937
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Caspase activation is required for gemcitabine activity in multiple myeloma cell lines.
    Nabhan C; Gajria D; Krett NL; Gandhi V; Ghias K; Rosen ST
    Mol Cancer Ther; 2002 Nov; 1(13):1221-7. PubMed ID: 12479703
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined use of subclinical hydroxyurea and CHK1 inhibitor effectively controls melanoma and lung cancer progression, with reduced normal tissue toxicity compared to gemcitabine.
    Oo ZY; Proctor M; Stevenson AJ; Nazareth D; Fernando M; Daignault SM; Lanagan C; Walpole S; Bonazzi V; Škalamera D; Snell C; Haass NK; Larsen JE; Gabrielli B
    Mol Oncol; 2019 Jul; 13(7):1503-1518. PubMed ID: 31044505
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks.
    Liu XJ; Nowak B; Wang YQ; Plunkett W
    Chin J Cancer; 2012 Aug; 31(8):373-80. PubMed ID: 22739266
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased cytotoxicity of 2',2'-difluoro-2'-deoxycytidine in human leukemic cell-lines after a preincubation with cyclopentenyl cytosine.
    Verschuur AC; Van Gennip AH; Leen R; Van Kuilenburg AB
    Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1517-21. PubMed ID: 15571289
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
    Komori S; Osada S; Mori R; Matsui S; Sanada Y; Tomita H; Tokuyama Y; Takahashi T; Yamaguchi K; Yoshida K
    Pancreas; 2010 Nov; 39(8):1284-92. PubMed ID: 20944490
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nucleoside and nucleobase analogs in cancer treatment: not only sapacitabine, but also gemcitabine.
    Muggia F; Diaz I; Peters GJ
    Expert Opin Investig Drugs; 2012 Apr; 21(4):403-8. PubMed ID: 22404148
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Human equilibrative nucleoside transporter 1, as a predictor of 5-fluorouracil resistance in human pancreatic cancer.
    Tsujie M; Nakamori S; Nakahira S; Takahashi Y; Hayashi N; Okami J; Nagano H; Dono K; Umeshita K; Sakon M; Monden M
    Anticancer Res; 2007; 27(4B):2241-9. PubMed ID: 17695509
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Apoptotic and antiproliferative effects of gemcitabine and gemcitabine plus Ara-C on blast cells from patients with blast crisis chronic myeloproliferative disorders.
    Santini V; Bernabei A; Gozzini A; Scappini B; Zoccolante A; D'Ippolito G; Figuccia M; Ferrini PR
    Haematologica; 1997; 82(1):11-5. PubMed ID: 9172997
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ribonucleotide reductase is an effective target to overcome gemcitabine resistance in gemcitabine-resistant pancreatic cancer cells with dual resistant factors.
    Minami K; Shinsato Y; Yamamoto M; Takahashi H; Zhang S; Nishizawa Y; Tabata S; Ikeda R; Kawahara K; Tsujikawa K; Chijiiwa K; Yamada K; Akiyama S; Pérez-Torras S; Pastor-Anglada M; Furukawa T; Yasuo T
    J Pharmacol Sci; 2015 Mar; 127(3):319-25. PubMed ID: 25837929
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interference of gemcitabine triphosphate with the measurements of deoxynucleotides using an optimized DNA polymerase elongation assay.
    Smid K; Van Moorsel CJ; Noordhuis P; Voorn DA; Peters GJ
    Int J Oncol; 2001 Jul; 19(1):157-62. PubMed ID: 11408937
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The role of cell cycle progression in radiosensitization by 2',2'-difluoro-2'-deoxycytidine.
    Ostruszka LJ; Shewach DS
    Cancer Res; 2000 Nov; 60(21):6080-8. PubMed ID: 11085531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival.
    Karnitz LM; Flatten KS; Wagner JM; Loegering D; Hackbarth JS; Arlander SJ; Vroman BT; Thomas MB; Baek YU; Hopkins KM; Lieberman HB; Chen J; Cliby WA; Kaufmann SH
    Mol Pharmacol; 2005 Dec; 68(6):1636-44. PubMed ID: 16126823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antitumor effects of KITC, a new resveratrol derivative, in AsPC-1 and BxPC-3 human pancreatic carcinoma cells.
    Bernhaus A; Ozsvar-Kozma M; Saiko P; Jaschke M; Lackner A; Grusch M; Horvath Z; Madlener S; Krupitza G; Handler N; Erker T; Jaeger W; Fritzer-Szekeres M; Szekeres T
    Invest New Drugs; 2009 Oct; 27(5):393-401. PubMed ID: 18841326
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 2'-C-cyano-2'-deoxy-1-beta-D-arabino-pentofuranosylcytosine: a novel anticancer nucleoside analog that causes both DNA strand breaks and G(2) arrest.
    Azuma A; Huang P; Matsuda A; Plunkett W
    Mol Pharmacol; 2001 Apr; 59(4):725-31. PubMed ID: 11259616
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A small-molecule blocking ribonucleotide reductase holoenzyme formation inhibits cancer cell growth and overcomes drug resistance.
    Zhou B; Su L; Hu S; Hu W; Yip ML; Wu J; Gaur S; Smith DL; Yuan YC; Synold TW; Horne D; Yen Y
    Cancer Res; 2013 Nov; 73(21):6484-93. PubMed ID: 24072748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.